## Chunk 1 (pages 1-27)

## Key points
- Document describes **Premier Inc.’s “Market Insights” Data & Analytics** offering (2025) and how it supports medical device companies across:
  - Market segmentation & account targeting
  - Supply chain resiliency and demand forecasting
  - Contract performance and portfolio analysis
  - Channel partner management
  - Procure-to-pay automation and applied sciences solutions (Premier Healthcare Database / outcomes research)
- **Premier’s Market Insights platform** positions itself to “Grow Revenue and Maximize Margin” by enabling:
  - Contract compliance monitoring for **SURPASS** and **AscenDrive**
  - Market share/opportunity identification and targeting aligned to customer goals
  - Demand forecasting and inventory optimization
  - Distributor performance/SLA monitoring and substitution tracking
- **Data source** summary:
  - Data types include “PO, invoice, inventory, cross-reference and master data”
  - “Data represents the U.S. acute care market”
  - “Customized dashboard highlighting manufacturer, product, revenues, and usage trends”
  - “Daily Data updates”
  - “ALL STAKEHOLDERS ACCESS THE SAME DATA SOURCE”
- A section focuses on **“Market Insights: B. Braun Awarded Contract Summary”** and recommended program support for specific categories/contracts.
- Example analytic views are shown (e.g., ASP trends, geographic market share maps, supply trends, ecosystem leakage heatmaps, and target prioritization frameworks).

## Decisions / confirmations
- Unknown (no explicit decisions/approvals stated in the provided pages).
- The “Recommended Premier/B Braun Market Insights Partnership” includes items labeled “Currently Subscribe” and “Current Investment (continues): $175,000/year” (implies continuation, but explicit decision not shown).

## Open questions
- Are the **“New Proposed Subscription”** items approved (yes/no unknown)?
- What is the final scope and timeline for the **“IV Categories (6) – Custom analytics services”** engagement beyond “6 Month engagement” (e.g., exact deliverables, milestones) (unknown)?
- Which specific stakeholders/owners at Premier and B. Braun are responsible for execution (unknown; roles mentioned but no names).

## Action items (with owners if present)
- **Potential next steps** section exists (“Potential Next Steps — Premier Market Insights & B Braun”), but specific actions/owners are not detailed (unknown).
- Proposed/ongoing work items (owners not named):
  - Continue compliance data/analytics/services with Premier Contract Success and Integration team for:
    - “Regional Anesthesia Trays and Supplies (SP-OR-2538) – Currently Subscribe”
    - “Safety IV Catheters (AD-NS-2112) – Currently Subscribe”
  - Expand compliance data/analytics/services (proposed):
    - “Regional Anesthesia Trays and Supplies (AD-OR-2538) – New Proposed Subscription”
    - “Safety IV Catheters (SP-NS-1627) – New Proposed Subscription”
  - Execute “IV Categories (6) – Custom analytics services” (6-month engagement), including a “Name-Blind Market Share Map (Acute)”.
  - Optional add-ons to consider:
    - “Capital Refresh Recency”
    - “DEHP/PVC-Free Targets”

## Notable metrics/claims (exact phrases where possible)
- Market Insights data source:
  - “$150 BILLION In supply & pharmacy ANNUAL SPEND”
  - “10+ YEARS OF HISTORY”
  - “25% TOTAL VOLUME ACROSS MAJOR DEMOGRAPHICS & GPO AFFILIATIONS”
  - “Daily Data updates”
- B. Braun performance (US Acute Care, Premier only):
  - “Total Revenue: $299M (YoY growth: +18.5%)”
  - “Market Total Revenue: $ 1.7B (YoY growth: +13.6%)”
  - “B. Bruan’s overall market share: 17.6%, up from 16.8% prior year”
  - “Safety IV Catheters: Growing less than 1% (0.8%) compared to market decline of -1.6%”
  - “IV Therapy – Infusion Devices : B. Braun market growth of 4.1% is lower than the market growth of 10.9%.”
- Supply chain / risk:
  - “PO Lines Past Due: B. Braun consistently maintained higher past-due rates than the competition, with both trending downward after early 2025.”
  - “Backorders/Cancellations: Backorders and cancellations for the competition spiked by late 2024, while B. Braun remained significantly lower throughout.”
  - “Baxter Products are projected to have the highest shortage risk”
  - “Shortage Condition Score: A custom metric summarizing key supply chain indicators such as PO lines past due, average lead time, backorders, etc.”
- Demand disruption / inventory coupling:
  - “Overall usage at the hospital level declined precipitously following the supply disruption, and has been recovering since, but is still below pre-Helene levels.”
  - “Overall days of supply peaked at ~33, ~2.2x pre-Helene levels, and has bled to 1.3x (remains elevated).”
  - “Q2 ‘25 – 8 days (~8% suppression of purchasing)”
  - “Q3 ‘25 – 5 days (~5% suppression of purchasing)”
- Commercial targeting frameworks:
  - “We isolate the 50 "Whale" accounts (bottom right) where you have significant revenue upside.”
  - Deliverable: “A prioritized "Target Action List" of blinded IDs mapped to Zip-3 geography for sales deployment.”
- Pricing/investment figures (Premier/B. Braun partnership):
  - “Current Investment (continues): $175,000/year”
  - “New Investment: $165,000/year (co-term with GPO contracts)”
  - “New Investment: $250,000; 6 Month engagement”
